Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Rheumatology Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of Factors Associated with Axial Spondyloarthritis Remission in a Cohort of Saudi Patients with Longstanding Disease: A Multicenter Prospective Cohort Study

Abstract

Background/Aim

Earlier treatment in axial spondyloarthritis (axSpA) was proposed to alter disease prognosis in this often-challenging condition. We aimed to assess the proportion of patients and prognostic factors associated with axSpA remission.

Objective

The aim was to determine the number of patients with Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) of <2.1 (inactive/moderate disease activity). We also evaluated global functioning and health using the Assessment of Spondyloarthritis International Society-Health Index (ASAS-HI).

Patients and Methods

Patients with axSpA who were receiving targeted synthetic/biological disease-modifying anti-rheumatic drug (ts/bDMARDs) treatments and visited the rheumatology units at two tertiary-care centers between December 2021 and December 2022 were prospectively interviewed. Data regarding patient demographics, disease features, active and previous ts/bDMARDs treatments, and disease activity scores were obtained. Patients were assessed using the ASDAS-CRP, ASDAS-erythrocyte sedimentation rate (ASDAS-ESR), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and ASAS-HI.

Results

Overall, 60 patients with axSpA were included in this study (women, n = 35); 25 (41.7%) and 36 (62.1%) achieved an ASDAS-CRP of <2.1 and an ASAS-HI of ≤5 (good health), respectively. Out of the 60 patients, 75% (n = 45) were treated with anti-tumor necrosis factor. Factors associated with achieving the target ASDAS-CRP included age ( = 0.019), sex ( = 0.015), employment status ( = 0.015), education level ( = 0.030), and the number of previous ts/bDMARDs treatments ( = 0.019). Additionally, the ASDAS-CRP strongly correlated with spinal pain and moderately correlated with the ASAS-HI, BASDAI, and the number of previous ts/bDMARDs treatments.

Conclusions

Remission was observed in 41.7% of patients, indicating a challenge in achieving target disease activity. However, 62.1% attained good health. Achieving remission was associated with younger age, male sex, a higher level of education, lower level of spinal pain, better global function by ASAS-HI, employment, and receiving their first ts/bDMARDs treatment. Our findings may potentially improve disease prognosis with the earlier use of ts/bDMARDs in those without favorable features by implementing an early axSpA intervention strategy.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971326045241016070431
2024-10-21
2024-11-26

  • From This Site

    /content/journals/crr/10.2174/0115733971326045241016070431
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Schwartzman S. Ruderman E.M. A road map of the axial spondyloarthritis continuum. Mayo Clin. Proc. 2022 97 1 134 145 10.1016/j.mayocp.2021.08.007 34801248
    [Google Scholar]
  2. van de Sande M.G.H. Elewaut D. Pathophysiology and immunolgical basis of axial spondyloarthritis. Best Pract. Res. Clin. Rheumatol. 2023 37 3 101897 10.1016/j.berh.2023.101897 38030467
    [Google Scholar]
  3. Magrey M.N. Danve A.S. Ermann J. Walsh J.A. Recognizing axial spondyloarthritis: A guide for primary care. Mayo Clin. Proc. 2020 95 11 2499 2508 10.1016/j.mayocp.2020.02.007 32736944
    [Google Scholar]
  4. Michelena X. López-Medina C. Marzo-Ortega H. Non-radiographic versus radiographic axSpA: What’s in a name? Rheumatology (Oxford) 2020 59 iv18 iv24 10.1093/rheumatology/keaa422 33053190
    [Google Scholar]
  5. D’Angelo S. Salvarani C. Marando F. Gualberti G. Novelli L. Curradi G. Tripepi G. Pitino A. Ramonda R. Marchesoni A. Residual disease in patients with axial spondyloarthritis: A post-hoc analysis of the QUASAR study. J. Clin. Med. 2022 11 12 3553 10.3390/jcm11123553 35743623
    [Google Scholar]
  6. Goh Y. Kwan Y.H. Leung Y.Y. Fong W. Cheung P.P. A cross-sectional study on factors associated with poor work outcomes in patients with axial spondyloarthritis in Singapore. Int. J. Rheum. Dis. 2019 22 11 2001 2008 10.1111/1756‑185X.13696 31576680
    [Google Scholar]
  7. Pina Vegas L. Sbidian E. Wendling D. Goupille P. Ferkal S. Le Corvoisier P. Ghaleh B. Luciani A. Claudepierre P. Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: Results from the DESIR cohort. Rheumatology (Oxford) 2022 61 4 1487 1495 10.1093/rheumatology/keab565 34270707
    [Google Scholar]
  8. Sieper J. Landewé R. Magrey M. Anderson J.K. Zhong S. Wang X. Lertratanakul A. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open 2019 5 1 e000917 10.1136/rmdopen‑2019‑000917 31245052
    [Google Scholar]
  9. Bubová K. Forejtová Š. Zegzulková K. Gregová M. Hušáková M. Filková M. Hořínková J. Gatterová J. Tomčík M. Szczuková L. Pavelka K. Šenolt L. Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: Baseline clinical characteristics and subset differences in a single-centre cohort. BMJ Open 2019 9 4 e024713 10.1136/bmjopen‑2018‑024713 30944131
    [Google Scholar]
  10. Bedaiwi M.K. AlRasheed R.F. Bin Zuair A. Alqurtas E.M. Baeshen M.O. Omair M.A. A cross-sectional study on clinical characteristics of Saudi axial spondylarthritis: Preliminary results. Eur. Rev. Med. Pharmacol. Sci. 2021 25 16 5241 5247 34486699
    [Google Scholar]
  11. Ulas S.T. Proft F. Diekhoff T. Rios V. Rademacher J. Protopopov M. Greese J. Eshed I. Adams L.C. Hermann K.G.A. Ohrndorf S. Poddubnyy D. Ziegeler K. Sex-specific diagnostic efficacy of MRI in axial spondyloarthritis: Challenging the ‘One Size Fits All’ notion. RMD Open 2023 9 4 e003252 10.1136/rmdopen‑2023‑003252 37899091
    [Google Scholar]
  12. Ramiro S. Nikiphorou E. Sepriano A. Ortolan A. Webers C. Baraliakos X. Landewé R.B.M. Van den Bosch F.E. Boteva B. Bremander A. Carron P. Ciurea A. van Gaalen F.A. Géher P. Gensler L. Hermann J. de Hooge M. Husakova M. Kiltz U. López-Medina C. Machado P.M. Marzo-Ortega H. Molto A. Navarro-Compán V. Nissen M.J. Pimentel-Santos F.M. Poddubnyy D. Proft F. Rudwaleit M. Telkman M. Zhao S.S. Ziade N. van der Heijde D. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann. Rheum. Dis. 2023 82 1 19 34 10.1136/ard‑2022‑223296 36270658
    [Google Scholar]
  13. van der Heijde D. Lie E. Kvien T.K. Sieper J. Van den Bosch F. Listing J. Braun J. Landewé R. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann. Rheum. Dis. 2009 68 12 1811 1818 10.1136/ard.2008.100826 19060001
    [Google Scholar]
  14. Ørnbjerg L.M. Linde L. Georgiadis S. Rasmussen S.H. Lindström U. Askling J. Michelsen B. Giuseppe D.D. Wallman J.K. Pavelka K. Závada J. Nissen M.J. Jones G.T. Relas H. Pirilä L. Tomšič M. Rotar Z. Geirsson A.J. Gudbjornsson B. Kristianslund E.K. van sder Horst-Bruinsma I. Loft A.G. Laas K. Iannone F. Corrado A. Ciurea A. Santos M.J. Santos H. Codreanu C. Akkoc N. Gunduz O.S. Glintborg B. Østergaard M. Hetland M.L. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration. Semin. Arthritis Rheum. 2022 56 152081 10.1016/j.semarthrit.2022.152081 35985172
    [Google Scholar]
  15. Georgiadis S. Ørnbjerg L.M. Michelsen B. Kvien T.K. Di Giuseppe D. Wallman J.K. Závada J. Provan S.A. Kristianslund E.K. Rodrigues A.M. Santos M.J. Rotar Ž. Pirkmajer K.P. Nordström D. Macfarlane G.J. Jones G.T. van der Horst-Bruinsma I. Hellamand P. Østergaard M. Hetland M.L. Cut-offs for disease activity states in axial spondyloarthritis with ankylosing spondylitis disease activity score (ASDAS) based on c-reactive protein and ASDAS based on erythrocyte sedimentation rate: Are they interchangeable? J. Rheumatol. 2024 51 7 673 677 10.3899/jrheum.2023‑1217 38621792
    [Google Scholar]
  16. Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing spondylitis disease activity score (ASDAS), ankylosing spondylitis quality of life scale (ASQoL), bath ankylosing spondylitis disease activity index (BASDAI), bath ankylosing spondylitis functional index (BASFI), bath ankylosing spondylitis global score (BAS-G), bath ankylosing spondylitis metrology index (BASMI), dougados functional index (DFI), and health assessment questionnaire for the spondylarthropathies (HAQ-S). Arthritis Care Res. (Hoboken) 2011 63 S11 S47 S58 10.1002/acr.20575 22588768
    [Google Scholar]
  17. van Weely S.F.E. van Denderen J.C. Steultjens M.P.M. van der Leeden M. Nurmohamed M.T. Dekker J. Dijkmans B.A.C. van der Horst-Bruinsma i.e. Moving instead of asking? Performance-based tests and BASFI-questionnaire measure different aspects of physical function in ankylosing spondylitis. Arthritis Res. Ther. 2012 14 2 R52 10.1186/ar3765 22401146
    [Google Scholar]
  18. El Miedany Y. Youssef S. Mehanna A. Shebrya N. Abu Gamra S. El Gaafary M. Defining disease status in ankylosing spondylitis: Validation and cross-cultural adaptation of the Arabic bath ankylosing spondylitis functional index (BASFI), the bath ankylosing spondylitis disease activity index (BASDAI), and the bath ankylosing spondylitis global score (BASG). Clin. Rheumatol. 2008 27 5 605 612 10.1007/s10067‑007‑0755‑2 18180979
    [Google Scholar]
  19. Rostom S. Benbouaaza K. Amine B. Bahiri R. Ibn Yacoub Y. Ali Ou Alla S. Abouqal R. Hajjaj-Hassouni N. Psychometric evaluation of the Moroccan version of the bath ankylosing spondylitis functional index (BASFI) and bath ankylosing spondylitis disease activity index (BASDAI) for use in patients with ankylosing spondylitis. Clin. Rheumatol. 2010 29 7 781 788 10.1007/s10067‑010‑1431‑5 20383548
    [Google Scholar]
  20. Di Carlo M. Lato V. Carotti M. Salaffi F. Clinimetric properties of the ASAS health index in a cohort of Italian patients with axial spondyloarthritis. Health Qual. Life Outcomes 2016 14 1 78 10.1186/s12955‑016‑0463‑1 27188166
    [Google Scholar]
  21. Kiltz U. van der Heijde D. Boonen A. Bautista-Molano W. Burgos-Vargas R. Chiowchanwisawakit P. Duruoz T. El-Zorkany B. Essers I. Gaydukova I. Géher P. Gossec L. Grazio S. Gu J. Khan M.A. Kim T.J. Maksymowych W.P. Marzo-Ortega H. Navarro-Compán V. Olivieri I. Patrikos D. Pimentel-Santos F.M. Schirmer M. van den Bosch F. Weber U. Zochling J. Braun J. Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS health index and the environmental item set: Translation and cross-cultural adaptation into 15 languages. RMD Open 2016 2 2 e000311 10.1136/rmdopen‑2016‑000311 27752358
    [Google Scholar]
  22. Kiltz U. Wendling D. Braun J. ASAS health index: The “All in One” for spondyloarthritis evaluation? J. Rheumatol. 2020 47 10 1457 1460 10.3899/jrheum.200708 33004479
    [Google Scholar]
  23. Min H.K. Lee J. Ju J.H. Park S.H. Kwok S.K. Predictors of assessment of spondyloarthritis international society (ASAS) health index in axial spondyloarthritis and comparison of ASAS health index between ankylosing spondylitis and nonradiographic axial spondyloarthritis: Data from the catholic axial spondyloarthritis cohort (CASCO). J. Clin. Med. 2019 8 4 467 10.3390/jcm8040467 30959846
    [Google Scholar]
  24. Regierer A.C. Weiß A. Kiltz U. Sieper J. Schwarze I. Bohl-Bühler M. Kellner H. Poddubnyy D. Zink A. Braun J. Listing J. Strangfeld A. The sensitivity to change of the ASAS health index in an observational real-life cohort study. J. Rheumatol. 2023 50 2 185 191 10.3899/jrheum.220212 35914790
    [Google Scholar]
  25. Sieper J. Rudwaleit M. Baraliakos X. Brandt J. Braun J. Burgos-Vargas R. Dougados M. Hermann K-G. Landewé R. Maksymowych W. van der Heijde D. The assessment of spondyloarthritis international society (ASAS) handbook: A guide to assess spondyloarthritis. Ann. Rheum. Dis. 2009 68 ii1 ii44 10.1136/ard.2008.104018 19433414
    [Google Scholar]
  26. Machado P.M. Landewé R. van der Heijde D. Ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann. Rheum. Dis. 2018 77 10 1539 1540 10.1136/annrheumdis‑2018‑213184 29453216
    [Google Scholar]
  27. Kaltsonoudis E. Pelechas E. Voulgari P. Drosos A. Maintained clinical remission in ankylosing spondylitis patients switched from reference infliximab to its biosimilar: An 18-month comparative open-label study. J. Clin. Med. 2019 8 7 956 10.3390/jcm8070956 31269678
    [Google Scholar]
  28. Kiltz U. van der Heijde D. Boonen A. Akkoc N. Bautista-Molano W. Burgos-Vargas R. Wei J.C.C. Chiowchanwisawakit P. Dougados M. Duruoz M.T. Elzorkany B.K. Gaydukova I. Gensler L.S. Gilio M. Grazio S. Gu J. Inman R.D. Kim T.J. Navarro-Compan V. Marzo-Ortega H. Ozgocmen S. Pimentel dos Santos F. Schirmer M. Stebbings S. Van den Bosch F.E. van Tubergen A. Braun J. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann. Rheum. Dis. 2018 77 9 1311 1317 10.1136/annrheumdis‑2017‑212076 29858176
    [Google Scholar]
  29. Shimabuco A.Y. Gonçalves C.R. Moraes J.C.B. Waisberg M.G. Ribeiro A.C.M. Sampaio-Barros P.D. Goldenstein-Schainberg C. Bonfa E. Saad C.G.S. Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors. Adv. Rheumatol. 2018 58 1 40 10.1186/s42358‑018‑0040‑x 30657103
    [Google Scholar]
  30. Chen H.H. Chen Y.M. Lai K.L. Hsieh T.Y. Hung W.T. Lin C.T. Tseng C.W. Tang K.T. Chou Y.Y. Wu Y.D. Huang C.Y. Hsieh C.W. Huang W.N. Chen Y.H. Gender difference in ASAS HI among patients with ankylosing spondylitis. PLoS One 2020 15 7 e0235678 10.1371/journal.pone.0235678 32645080
    [Google Scholar]
  31. Omair M.A. AlDuraibi F.K. Bedaiwi M.K. Abdulaziz S. Husain W. El Dessougi M. Alhumaidan H. Al Khabbaz H.J. Alahmadi I. Omair M.A. Al Saleh S. Alismael K. Al Awwami M. Prevalence of HLA-B27 in the general population and in patients with axial spondyloarthritis in Saudi Arabia. Clin. Rheumatol. 2017 36 7 1537 1543 10.1007/s10067‑017‑3655‑0 28456926
    [Google Scholar]
  32. Ziade N. Abi Karam G. Merheb G. Mallak I. Irani L. Alam E. Messaykeh J. Menassa J. Mroue’ K. Uthman I. Masri A.F. Ghorra P. Witte T. Baraliakos X. HLA-B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study. Int. J. Rheum. Dis. 2019 22 4 708 714 10.1111/1756‑185X.13487 30729696
    [Google Scholar]
  33. Al-Attia H.M. Al-Amiri N. HLA-B27 in healthy adults in UAE. An extremely low prevalence in Emirian Arabs. Scand. J. Rheumatol. 1995 24 4 225 227 10.3109/03009749509100878 7481586
    [Google Scholar]
  34. Ziade N.R. HLA B27 antigen in Middle Eastern and Arab countries: Systematic review of the strength of association with axial spondyloarthritis and methodological gaps. BMC Musculoskelet. Disord. 2017 18 1 280 10.1186/s12891‑017‑1639‑5 28662723
    [Google Scholar]
  35. Favero M. Ometto F. Belluzzi E. Cozzi G. Scagnellato L. Oliviero F. Ruggieri P. Doria A. Lorenzin M. Ramonda R. Fetuin-A: A novel biomarker of bone damage in early axial spondyloarthritis. Results of an interim analysis of the SPACE study. Int. J. Mol. Sci. 2023 24 4 3203 10.3390/ijms24043203 36834615
    [Google Scholar]
  36. Ciurea A. Götschi A. Kissling S. Bernatschek A. Bürki K. Exer P. Nissen M.J. Möller B. Scherer A. Micheroli R. Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry. RMD Open 2023 9 2 e002956 10.1136/rmdopen‑2022‑002956 37277211
    [Google Scholar]
  37. Helliwell P.S. Gladman D.D. Chakravarty S.D. Kafka S. Karyekar C.S. You Y. Campbell K. Sweet K. Kavanaugh A. Gensler L.S. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. RMD Open 2020 6 1 e001149 10.1136/rmdopen‑2019‑001149 32209721
    [Google Scholar]
  38. Kwok T.S.H. Sutton M. Pereira D. Cook R.J. Chandran V. Haroon N. Inman R.D. Gladman D.D. Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis. Ann. Rheum. Dis. 2022 81 12 1678 1684 10.1136/ard‑2022‑222537 35973805
    [Google Scholar]
  39. Robinson P.C. Brown M.A. The window of opportunity: A relevant concept for axial spondyloarthritis. Arthritis Res. Ther. 2014 16 3 109 10.1186/ar4561 25167369
    [Google Scholar]
  40. Mauro D. Forte G. Poddubnyy D. Ciccia F. The role of early treatment in the management of axial spondyloarthritis: Challenges and opportunities. Rheumatol. Ther. 2024 11 1 19 34 10.1007/s40744‑023‑00627‑0 38108992
    [Google Scholar]
  41. Leirisalo-Repo M. What is the best treatment strategy for early RA? Best Pract. Res. Clin. Rheumatol. 2013 27 4 523 536 10.1016/j.berh.2013.10.002 24315052
    [Google Scholar]
  42. Quinn M.A. Conaghan P.G. Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: What is the evidence? Br. J. Rheumatol. 2001 40 11 1211 1220 10.1093/rheumatology/40.11.1211 11709604
    [Google Scholar]
/content/journals/crr/10.2174/0115733971326045241016070431
Loading
Factors Associated with Axial Spondyloarthritis Remission in a Cohort of Saudi Patients with Longstanding Disease: A Multicenter Prospective Cohort Study
Bentham Science Publishers ; https://doi.org/10.2174/0115733971326045241016070431
/content/journals/crr/10.2174/0115733971326045241016070431
/content/journals/crr/10.2174/0115733971326045241016070431
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: disease activity index ; biological therapy ; Axial spondyloarthritis ; treat-to-target ; remission ; prognosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test